Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 8/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7512781 | 0.81 | ITK (0.54) | ITKGSK3BRAB9ANPC1AURKA | |
| SCHEMBL5756512 | 0.78 | ITK (0.54) | ITKRAB9ANPC1AURKAAURKB | |
| SCHEMBL5759131 | 0.78 | ITK (0.48) | ITKRAB9ANPC1KDRCHEK1 | |
| SCHEMBL6487335 | 0.76 | ITK (0.49) | ITKRAB9ANPC1AURKAAURKB | |
| SCHEMBL2876288 | 0.74 | ITK (0.60) | ITKGSK3BRAB9ANPC1AOC3 | |
| SCHEMBL21945267 | 0.73 | ITK (0.49) | ITKGSK3BRAB9ANPC1AOC3 | |
| SCHEMBL1901060 | 0.72 | GSK3B (0.56) | ITKGSK3BRAB9ANPC1AOC3 | |
| SCHEMBL29631691 | 0.72 | RAB9A (0.74) | ITKGSK3BRAB9ANPC1AOC3 | |
| SCHEMBL374022 | 0.72 | RAB9A (0.74) | ITKGSK3BRAB9ANPC1AOC3 | |
| SCHEMBL5247261 | 0.72 | GSK3B (0.49) | ITKGSK3BRAB9ANPC1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253697-A1 | Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-10-08 | — | — | US | claimed |
| EP-1633738-A2 | NOVEL INDOLE DERIVATIVES, METHOD OF PREPARING SAME IN THE FORM OF MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, KDR INHIBITORS | Aventis Pharma S.A. (FR) | 2006-03-15 | — | — | EP | claimed |
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-02 | — | — | US | claimed |
| WO-2004096792-A2 | NOVEL INDOLE DERIVATIVES, METHOD OF PREPARING SAME IN THE FORM OF MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, KDR INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | WO | claimed |
| US-20090253697-A1 | Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-10-08 | — | — | US | disclosed |
| EP-1633738-A2 | NOVEL INDOLE DERIVATIVES, METHOD OF PREPARING SAME IN THE FORM OF MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, KDR INHIBITORS | Aventis Pharma S.A. (FR) | 2006-03-15 | — | — | EP | disclosed |
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-02 | — | — | US | disclosed |
| WO-2004096792-A2 | NOVEL INDOLE DERIVATIVES, METHOD OF PREPARING SAME IN THE FORM OF MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, KDR INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | FLT4, KDR, CYP3A4 | ITK 1186/4885GSK3B 1129/4885RAB9A 4173/4885 |
| US-20090253697-A1 | Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors | KDR, FLT1, FLT4 | ITK 1042/4885GSK3B 104/4885RAB9A 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.